Fasoracetam is a synthetic experimental racetam developed in Japan under the research code NS-105. Its proposed activity involves neurotransmitter systems, including metabotropic glutamate signaling. The entry reviews preliminary attention and cognition research, including a small ADHD study in adolescents with particular genetic variants, while noting the need for replication.
What Is Fasoracetam?
Fasoracetam is a synthetic member of the racetam family of experimental cognitive compounds. It was developed in Japan and investigated as a potential cognition-enhancing drug under the research code NS-105. The compound later became associated with NeuroBiological Technologies and related development efforts, including work examining whether biological markers could identify people more likely to respond. Unlike stimulant medicines used for attention-deficit/hyperactivity disorder (ADHD), fasoracetam has generally been described in the research and nootropic literature as producing a comparatively calming or low-activation profile. That description is not a clinical conclusion: human studies have been small, and fasoracetam has not established safety or efficacy for routine medical use.
Interest in fasoracetam increased after a pilot ADHD study examined adolescents with changes in genes related to metabotropic glutamate receptor signaling. The study was notable because it used a biologically informed subgroup rather than treating ADHD as a single uniform disorder. Participants with certain mGluR-pathway variants appeared to show symptom improvement in the reported trial, but the findings require replication in larger, randomized, independently conducted studies. The result should therefore be viewed as hypothesis-generating rather than proof that genetic testing can determine who should take fasoracetam. No major regulatory authority has approved fasoracetam for ADHD, cognition, anxiety, depression, stroke recovery, or any other indication.
Quick Reference
Member reference tables summarize the compound's research parameters.
A small open-label clinical study explored fasoracetam in adolescents with ADHD selected for glutamatergic gene-network variants. Findings were exploratory and require controlled replication.
Preclinical learning models
Animal and laboratory research has examined effects on learning, memory-related behavior, and neurotransmitter systems; these findings do not establish cognitive benefit in healthy people.
Glutamatergic Signaling
Emerging Evidence
Metabotropic glutamate receptor modulation
Fasoracetam has been described as a modulator of metabotropic glutamate receptor pathways in preclinical literature. Translation from receptor pharmacology to clinical outcomes remains uncertain.
Potential network normalization
Its development rationale included disorders involving altered glutamatergic signaling, but no established therapeutic indication has been confirmed by robust randomized trials.
Cholinergic & GABAergic Systems
Preliminary Data
Acetylcholine-related activity
Preclinical reports suggest influences on cholinergic signaling. Human efficacy for memory, alertness, or age-related cognitive symptoms is not established.
GABA-B receptor-related effects
Laboratory findings have also implicated GABA-B receptor systems, supporting mechanistic interest but not a validated clinical use or safety profile.
Mood & Anxiety-Related Effects
Emerging Evidence
Subjective calmness or motivation
Anecdotal reports describe variable changes in mood, drive, or calmness; these observations are not controlled clinical evidence and may reflect expectancy or individual sensitivity.
No established psychiatric indication
Fasoracetam is not an established treatment for depression, anxiety, bipolar disorder, or other mood disorders. Psychiatric symptoms warrant professional assessment.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
The described verification process includes looking for a current, lot-matched COA that identifies the material as fasoracetam and includes the supplier, batch number, date, and analytical method.
Verified Marker
Independent identity and purity testing
Prefer third-party HPLC or LC-MS documentation with a stated purity result, chromatogram where available, and testing performed on the finished batch.
Verified Marker
Contaminant screening
Documentation should address heavy metals and, where relevant, microbiological contaminants and residual solvents using recognized laboratory methods.
Acceptable Range
Accurate capsule or powder dosing
For capsules, verify declared milligrams per capsule and excipients. For powder, a calibrated milligram scale is essential; volumetric scoops are not sufficiently accurate.
Quality Concern
Unverifiable or generic testing documents
The listed research text specifies avoiding products with no batch-linked COA, copied reports lacking laboratory details, implausible purity claims, missing dosage information, or packaging that does not identify the responsible seller.